Ibrutinib therapy for lymphoplasmacytic lymphoma

Am J Hematol. 2017 Sep;92(9):E542-E544. doi: 10.1002/ajh.24795. Epub 2017 Jun 9.

Authors

Margaret J Helber^{1

2}, Jeremiah E Moore¹, AnnaLynn M Williams^{2

3}, Philip J Meacham^{2

3}, Paul G Rothberg⁴, Clive S Zent^{2

5}

Affiliations

¹ Department of Pharmacy, University of Rochester Medical Center, Rochester, New York.
² Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, New York.
³ Department of Public Health Sciences, University of Rochester Medical Center, Rochester, New York.
⁴ Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, New York.
⁵ Department of Medicine, University of Rochester Medical Center, Rochester, New York.

PMID: 28543765
DOI: 10.1002/ajh.24795

No abstract available

Publication types

Letter
Observational Study
Research Support, Non-U.S. Gov't

MeSH terms

Adenine / analogs & derivatives
Adult
Agammaglobulinaemia Tyrosine Kinase
Aged
Aged, 80 and over
Antineoplastic Agents / adverse effects
Antineoplastic Agents / pharmacology
Antineoplastic Agents / therapeutic use*
Female
Humans
Immunoglobulin M / blood
Kidney Failure, Chronic / etiology
Male
Middle Aged
Molecular Targeted Therapy*
Neoplasm Proteins / antagonists & inhibitors
Paraproteins / analysis
Piperidines
Protein-Tyrosine Kinases / antagonists & inhibitors
Pyrazoles / adverse effects
Pyrazoles / pharmacology
Pyrazoles / therapeutic use*
Pyrimidines / adverse effects
Pyrimidines / pharmacology
Pyrimidines / therapeutic use*
Salvage Therapy
Treatment Outcome
Waldenstrom Macroglobulinemia / complications
Waldenstrom Macroglobulinemia / drug therapy*

Substances

Antineoplastic Agents
Immunoglobulin M
Neoplasm Proteins
Paraproteins
Piperidines
Pyrazoles
Pyrimidines
ibrutinib
Protein-Tyrosine Kinases
Agammaglobulinaemia Tyrosine Kinase
Adenine